Amgen 2015 Annual Report Download - page 126

Download and view the complete annual report

Please find page 126 of the 2015 Amgen annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 132

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106
  • 107
  • 108
  • 109
  • 110
  • 111
  • 112
  • 113
  • 114
  • 115
  • 116
  • 117
  • 118
  • 119
  • 120
  • 121
  • 122
  • 123
  • 124
  • 125
  • 126
  • 127
  • 128
  • 129
  • 130
  • 131
  • 132

F-48
19. Segment information
We operate in one business segment—human therapeutics. Therefore, results of our operations are reported on a consolidated
basis for purposes of segment reporting, consistent with internal management reporting. Enterprise-wide disclosures about product
sales; revenues and long-lived assets by geographic area; and revenues from major customers are presented below.
Revenues
Revenues were as follows (in millions):
Years ended December 31,
2015 2014 2013
Product sales:
ENBREL $ 5,364 $ 4,688 $ 4,551
Neulasta® 4,715 4,596 4,392
Aranesp® 1,951 1,930 1,911
EPOGEN® 1,856 2,031 1,953
Sensipar®/Mimpara®1,415 1,158 1,089
XGEVA® 1,405 1,221 1,019
Prolia® 1,312 1,030 744
NEUPOGEN® 1,049 1,159 1,398
Vectibix® 549 505 389
Nplate® 525 469 427
Kyprolis® 512 331 73
Other 291 209 246
Total product sales 20,944 19,327 18,192
Other revenues 718 736 484
Total revenues $ 21,662 $ 20,063 $ 18,676
Geographic information
Outside the United States, we sell products principally in Europe. The geographic classification of product sales was based
on the location of the customer. The geographic classification of all other revenues was based on the domicile of the entity from
which the revenues were earned.
Certain geographic information with respect to revenues and long-lived assets (consisting of property, plant and equipment)
was as follows (in millions):
Years ended December 31,
2015 2014 2013
Revenues:
United States $ 17,167 $ 15,396 $ 14,480
Rest of the world (ROW) 4,495 4,667 4,196
Total revenues $ 21,662 $ 20,063 $ 18,676